Advarra

AUGUST 16, 2022

The law established the Office of Orphan Products Development , providing financial incentives for pharmaceutical companies to develop orphan drugs and making it more viable to invest in orphan drug research and development. The impact was clear: Between 1983 and 2020, FDA approved 599 orphan drugs.

Disease 52

Disease Clinical Trials FDA Approval FDA 52

The Pharma Data

NOVEMBER 10, 2020

Dr. Liu shared his over 30 years of R&D experience in drug development both in the global pharmaceutical companies and world renowned scientific research institutions. By joining Innovent, Dr. Liu will be responsible for global R & D, pipeline strategy, business development and international operations.

Biosimilars 52

Biosimilars Clinical Trials International Clinical Development 52

Conversations in Drug Development Trends

FEBRUARY 21, 2024

As a result, we ensure collection of all urine and fecal samples over a period ranging between five to seven days, modifying the participant diet if needed.

Clinical Trials 80

Clinical Trials Pharmacy Clinical Pharmacology FDA 80

DrugBank

FEBRUARY 12, 2025

The pharmaceutical industry grapples with the persistent challenge of high attrition rates and escalating costs inherent in drug development. This necessitates exploring alternative strategies to expedite drug discovery and optimize resource allocation.

Cell Based Assays 52

Cell Based Assays Drugs Pharmacokinetics Disease 52

Agency IQ

JUNE 9, 2023

The problems: Although the current regulation stimulated orphan drug research, it didn’t do enough The regulation fostered development of medicines for rare diseases since implementation, but not enough. Orphan drug developers may set higher prices to recoup their return on investment lost due to the haircut.

Marketing 40

Marketing Regulations Biosimilars Drugs 40

NIH Director's Blog: Drug Development

FEBRUARY 16, 2021

ACTIV was founded last April to accelerate drug research that typically requires more than a decade of clinical ups and downs to develop a safe, effective therapy. And ACTIV has indeed moved at unprecedented speed since its launch.

Clinical Trials 52

Clinical Trials Trials Hospitals Vaccine 52

Codon

JUNE 2, 2024

While fundamental research is often productive in mice, translational drug research tends to be relatively intolerant to biological differences. In cancer, the focus of Little’s ambitions, mouse models leave much to be desired.

Laboratories 136

Laboratories Research Disease Science 136

Drug Target Review

FEBRUARY 11, 2025

Drug development: addressing complexity and success rates Drug development is a complex and expensive process, requiring multidisciplinary expertise and high-risk financial investments. The financial burden of drug development is substantial, often exceeding $2 billion per drug.

Drug Development 59

Drug Development Bioinformatics Drugs Small Molecule 59